PLAINSBORO, N.J., July 12, 2007 (PRIME NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it released the Uni-CP(TM) Compression Plating system, the latest addition to its extremity fixation product line. The Uni-CP(TM) Plating System has an FDA clearance in the United States and a CE Mark Certification in the European Union. Integra will feature the product at the American Orthopaedic Foot and Ankle Society summer meeting, Toronto, Ontario, Canada, July 13-15, 2007.
The Uni-CP(TM) Plate is the newest addition to the Uniclip(R) Compression System, which includes a line of compression plates and staples designed for the correction and stabilization of osteotomies and fusions in the hand and foot. Each product employs a patented diamond shaped bridge design to provide compression through controlled deformation of the implant by the surgeon.
The Uni-CP(TM) Plate adds the following features and benefits to the Uniclip(R) Compression System:
* Screw fixation when additional pull out strength is desired; * Patented Surfix(TM) locking technology that enables the surgeon to securely position the plate for optimal deformity correction; * 2- and 4-hole locking plate designs for increased stability.
"The Uni-CP(TM) Plate adds a lot of flexibility to the Uniclip(R) Compression System. The surgeon can use a staple for less demanding procedures or switch to a plate with 2 or 4 locking screws when additional fixation is needed, all within a single system. The use of the Uni-CP locking compression plate in osteoporotic bone has proven invaluable in complex reconstructive foot surgery," said Stephen Conti, MD, Director, Division of Foot and Ankle Surgery, Allegheny General Hospital, Pittsburgh, Pennsylvania.
Compression staples and plates are used extensively in mid and hind foot reconstruction procedures. Based on available procedural data, Integra estimates that the Uniclip(R) Compression System can be used in over 40,000 procedures annually.
Integra's Extremity Reconstruction sales organization will sell the Uni-CP(TM) plate. The Extremity Reconstruction sales force includes over 75 U.S. sales specialists who focus on lower extremity fixation, upper extremity fixation, wound repair, tendon protection, and peripheral nerve repair/protection.
Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing, and marketing of cost-effective surgical implants and medical instruments. Our products, used primarily in neurosurgery, extremity reconstruction, orthopedics and general surgery, are used to treat millions of patients every year. Integra's headquarters are in Plainsboro, New Jersey, and we have research and manufacturing facilities throughout the world. Please visit our website at www.Integra-LS.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use of the Uniclip(R) Compression System. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use this product may affect the prospects for its use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the "Risk Factors" included in Item lA of Integra's Annual Report on Form 10-K for the year ended December 31, 2006, and information contained in subsequent filings with the Securities and Exchange Commission, could affect actual results.
IART P